At a glance
- Originator Bayer Schering Pharma
- Developer Bayer HealthCare Pharmaceuticals
- Class Cardiotonics
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Heart failure; Ischaemic heart disorders
Most Recent Events
- 15 Jun 2004 Discontinued - Preclinical for Ischaemic heart disorders (unspecified route)
- 31 Dec 1994 Discontinued - Uspecified phase in Heart failure in USA (Unknown route)
- 31 Dec 1994 Preclinical development for Ischaemic heart disorders (Unknown route)